View Older Stories View More Recent Stories

Sep 1, 2022 08:00AM Arcutis to Present at Upcoming Investor Conference
Sep 1, 2022 08:00AM Arcutis to Present at Upcoming Investor Conference
Aug 30, 2022 10:00AM NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING
Aug 23, 2022 08:00AM Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
Aug 23, 2022 08:00AM Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
Aug 22, 2022 08:00AM Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients
Aug 22, 2022 08:00AM Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients
Aug 10, 2022 09:00AM Arcutis Biotherapeutics Inc. (ARQT) Launches ZORYVE in the US
Aug 10, 2022 09:00AM Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older
Aug 10, 2022 09:00AM Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older
Aug 4, 2022 04:01PM Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update
Aug 4, 2022 04:01PM Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update
Aug 4, 2022 08:00AM Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
Aug 4, 2022 08:00AM Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
Aug 3, 2022 05:55PM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2022 07:30AM Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE™ (roflumilast) Cream 0.3% for Plaque Psoriasis
Aug 1, 2022 07:30AM Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE™ (roflumilast) Cream 0.3% for Plaque Psoriasis
Jul 29, 2022 04:05PM Arcutis Biotherapeutics (ARQT) Announces FDA Approval of ZORYVE Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12+
Jul 29, 2022 04:05PM FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
Jul 29, 2022 04:05PM FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
Jul 11, 2022 08:04AM Arcutis Biotherapeutics Inc. (ARQT) Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
Jul 11, 2022 08:00AM Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
Jul 11, 2022 08:00AM Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
Jul 5, 2022 04:04PM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 6, 2022 07:30AM Arcutis Biotherapeutics (ARQT) Reports Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3%
Jun 6, 2022 07:30AM Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Jun 6, 2022 07:30AM Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Jun 3, 2022 04:16PM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 25, 2022 10:33AM CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
May 25, 2022 10:33AM CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
May 25, 2022 08:00AM Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
May 25, 2022 08:00AM Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
May 5, 2022 04:01PM Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 04:01PM Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 08:00AM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 6, 2022 08:00AM Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis
Apr 6, 2022 08:00AM Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis
Mar 28, 2022 08:00AM Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts
Mar 28, 2022 08:00AM Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts
Mar 25, 2022 07:31AM Arcutis Biotherapeutics' (ARQT) Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
Mar 25, 2022 07:31AM Arcutis Biotherapeutics Inc. (ARQT) Reports Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
Mar 25, 2022 07:30AM Arcutis Biotherapeutics Inc. (ARQT) Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trial
Mar 25, 2022 07:30AM Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
Mar 25, 2022 07:30AM Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
Mar 25, 2022 07:30AM Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
Mar 25, 2022 07:30AM Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
Mar 22, 2022 08:00AM National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments
Mar 22, 2022 08:00AM National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments
Mar 21, 2022 08:00AM Arcutis to Host Investor Day on March 28
Mar 21, 2022 08:00AM Arcutis to Host Investor Day on March 28
View More Recent Stories View Older Stories